Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis

No therapy for non-alcoholic steatohepatitis (NASH) has been approved so far. Roux-en-y gastric bypass (RYGB) is emerging as a therapeutic option, although its effect on NASH and related hepatic molecular pathways is unclear from human studies. We studied the effect of RYGB on pre-existent NASH and hepatic mitochondrial dysfunction-a key player in NASH pathogenesis-in a novel diet-induced mouse model nicely mimicking human disease.


Published in:
Gut, 64, 4, 673-83
Year:
2014
ISSN:
1468-3288
Laboratories:




 Record created 2015-04-14, last modified 2018-03-17


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)